Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization

IntroductionUp to 50% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line therapy. Tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR)-T cell therapy, is approved for patients with relapsed/refractory (r/r) DLBCL in the third-line setting. Pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Phoebe Joy Ho, Vinay Vanguru, Cale S. Burge, Rebecca Wayte, Christina Brown, Christian E. Bryant, Scott Dunkley, Derek McCulloch, Liane Khoo, James Favaloro, Anthony Jeffrey, Annie Solterbeck, Stephen Larsen, Edward Abadir
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
r/r DLBCL
CAR-T
real-world
tisagenlecleucel
relapsed
refractory
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1633644/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items